Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension

International Journal of Urology

Volumn 6, Issue 7, 1999, Pages 346-354

  Fawzy, Ahmed ^a,b   Hendry, Angela ^a   Cook, Eileen ^a   Gonzalez, Francisco ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^b Urologic Institute of New Orleans   (United States)

Author keywords

1 adrenoceptor antagonists; Benign prostatic hyperplasia; Doxazosin; Hypertension

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFICACY; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SOMNOLENCE; SYMPTOM; URINE FLOW RATE; VERTIGO;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DOXAZOSIN; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; QUESTIONNAIRES; SAFETY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URODYNAMICS;

EID: 0032801813     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.1999.00071.x     Document Type: Article

References (21)

1. 1 Garraway WM, Russell EBAW, Lee RJ, Collins GN, McKelvie GB, Hehir M, Rogers ACN, Simpson RJ. Impact of previously unrecognised benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br. J. Gen. Pract. 1993; 43: 318-21.
2. 2 Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of benign prostatic hyperplasia with age. J. Urol. 1984; 132:474-9.
3. 3 Chute CG, Panser L, Girman CJ et al. The prevalence of prostatism: A population-based survey of urinary symptoms. J. Urol. 1993; 150: 85-9.
4. 4 Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hyperplasia in the community. Lancet 1991; 338: 469-71.
5. 5 Joint National Committee. 1993 report of the JNC on detection, evaluation and treatment of high blood pressure. Arch. Intern. Med. 1993; 153: 154-83.
6. 6 Kaplan NM. Clinical hypertension, 6th edn. Williams & Wilkins, Baltimore, 1994; 1-22.
7. 7 Pool JL. Doxazosin: A new approach to hypertension and benign prostatic hyperplasia. Br. J. Clin. Pract. 1996; 50: 154-63.
8. 8 Boyle P, Napalkov P. Epidemiology of benign prostatic hyperplasia: Current perspectives. Eur. Urol. 1996, 29 (Suppl. I): 7-11.
9. 9 Christensen MM, Holme JB, Rasmussen PC et al. Doxazosin in short-term treatment of prostatic obstruction: A double-blind placebo-controlled study. Scand. J. Urol. Nephrol. 1993; 27: 39-44.
10. 10 Holme JB, Christensen MM, Rasmussen PC et al. 29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. Scand. J. Urol. Nephrol. 1994; 28: 77-82.
11. 11 Kirby RS. Doxazosin in benign prostatic hyperplasia (BPH): Differential effects on the blood pressure of normotensive and hypertensive men. Urology 1995; 46: 182-6.
12. 12 Gillenwater JY, Conn RL, Chrysant SG et al., for the Multicenter Study Group. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: A double-blind, placebo-controlled, dose response multicenter study. J. Urol. 1995; 154: 110-15.
13. 13 Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K, Dias N, for the Multicenter Study Group. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: A multicenter study. J. Urol. 1995; 154: 105-9.
14. 14 Lepor H, Kaplan SA, Klimberg I et al., for the Multicenter Study Group. Doxazosin in benign prostatic hyperplasia: Long-term efficacy and safety in hypertensive and normotensive patients. J. Urol. 1997; 157: 525-30.
15. 15 Boyarsky S, Jones G, Paulson DF, Prout GR. A new look at bladder neck obstruction by the Food and Drug Administration regulators: Guidelines for investigation of benign prostatic hypertrophy. Trans. Am. Ass. Genito-Urin Surg. 1977; 68: 29-32.
16. 16 Fawzy A. Doxazosin in the treatment of benign prostatic hyperplasia: Early onset of action and efficacy of lower dose therapy. Eur. Urol. 1996; 30 (Suppl. 2): 101.
17. 17 Janknegt RA, Chapple CR. Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia: Analysis of five Studies. Eur. Urol. 1993; 24: 319-26.
18. 18 Andersson K-E, Wyllie MG. The importance of understanding the sympathetic cascade in the treatment of the whole benign prostatic hyperplasia patient. Eur. Urol. 1996; 30 (Suppl. 2): 103.
19. 19 Roehrborn CG, Siegel RL. Safety and efficacy of doxazosin in benign prostatic hyperplasia: A pooled analysis of three double-blind, placebo-controlled studies. Urology 1996; 48: 406-15.
20. 20 Lepor H, for the Terazosin Research Group. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology 1995; 45: 406-13.
21. 21 Grimm RH, Grandits GA, Schoenberger J et al., for the TOMHS Research Group. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women in the Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997; 29: 8-14.